

The patent application relating to activation of Immunicum's COMBIG-cells for therapeutic cancer vaccination will be granted in the US

GOTHENBURG December 15, 2014. Immunicum AB (publ) today announced that the United States Patent and Trademark Office (USPTO) has submitted a "Notice of Allowance" regarding patent application 13/522,741 and thereby intends to approve Immunicum's patent to protect the way to activate the Company's cancer vaccine cells in the US market.

- This strengthens our intellectual property further in the US market, where we will now have two approved patents to protect our technology. The importance of this for future licensing discussions is substantial, says Jamal El-Mosleh, CEO of Immunicum.

The Company's unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

Alex Karlsson-Parra, CSO, Immunicum
Phone: +46 (0) 705 16 75 79
alex.karlsson-parra@immunicum.com

The company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se

About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the company's most advanced project - INTUVAX[®] against

renal cancer - is expected to start in early 2015. The project portfolio contains three further projects against various tumor diseases, including liver cancer.

www.immunicum.com